| Item Type | Name |
|
Concept
|
Cell Separation
|
|
Concept
|
Clinical Trials, Phase I as Topic
|
|
Academic Article
|
On the TRAIL toward death receptor-based cancer therapeutics.
|
|
Academic Article
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
|
Academic Article
|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
|
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
|
Academic Article
|
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
|
|
Academic Article
|
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
|
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
|
Academic Article
|
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
|
|
Academic Article
|
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
|
|
Academic Article
|
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
|
|
Academic Article
|
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
|
|
Academic Article
|
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
|
|
Academic Article
|
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
|
|
Academic Article
|
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
|
|
Academic Article
|
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
|
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
|
Academic Article
|
CD40 ligation reverses T cell tolerance in acute myeloid leukemia.
|
|
Academic Article
|
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
|
|
Academic Article
|
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
|
|
Academic Article
|
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
|
|
Academic Article
|
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
|
|
Academic Article
|
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.
|
|
Academic Article
|
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
|
|
Academic Article
|
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
|
|
Academic Article
|
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial.
|
|
Academic Article
|
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
|
|
Academic Article
|
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
|
|
Academic Article
|
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
|
|
Academic Article
|
Phase 2 trial of talabostat in stage IV melanoma.
|
|
Academic Article
|
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
|
|
Academic Article
|
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
|
|
Academic Article
|
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
|
|
Academic Article
|
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
|
|
Academic Article
|
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
|
Academic Article
|
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
|
|
Academic Article
|
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
|